文章基本信息

标题：Phosphatidylinositol increases HDL-C levels in humans
本地全文：下载
作者：Jim W. Burgess ; Tracey A-M. Neville ; Patricia Rouillard 等
期刊名称：JLR Papers In Press
印刷版ISSN：0022-2275
电子版ISSN：1539-7262
出版年度：2005
卷号：46
期号：02
页码：350-355
DOI：10.1194/jlr.M400438-JLR200
出版社：American Society for Biochemistry and Molecular Biology
摘要：Studies have shown that phosphatidylinositol (PI) can stimulate reverse cholesterol transport by enhancing the flux of cholesterol into HDL and by promoting the transport of high density lipoprotein-cholesterol (HDL-C) to the liver and bile. The goal of this study was to determine the safety and therapeutic value of PI after oral administration to normolipidemic human subjects. We performed a randomized 2 week study in 16 normolipidemic subjects. Subjects received either 2.8 or 5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI significantly affected the levels of HDL-C and triglyceride in the plasma of subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C, whereas the high dose showed an increase of 18% over the 2 week period. Both low- and high-dose groups showed significant increases in plasma apolipoprotein A-I. The high dose of PI also decreased plasma triglycerides by 36% in the fed subjects. These data suggest that after only 2 weeks, PI may have a comparable therapeutic value to niacin, with negligible side effects. Abbreviations: CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; PI, phosphatidylinositol
关键词：high density lipoprotein-cholesterol • cholesterol • triglycerides • HDL elevating agents